Blood Res.  2022 Dec;57(4):250-255. 10.5045/br.2022.2022097.

Epigenetic and genetic investigation of SOCS-1 gene in patients with multiple myeloma

• Tuncel FC
• Serin I
• Pehlivan S
• Oyaci Y
• Pehlivan M

• KMID: 2537547
• DOI: http://doi.org/10.5045/br.2022.2022097

Abstract

Background
The suppressor of cytokine signaling-1 (SOCS-1) functions to induce an appropriate immune response and is an essential physiological regulator of interferon signaling. DNA methylation involves adding a methyl group to the carbon 5 position of cytosine. Besides comparing SOCS-1 gene methylation status between patients with multiple myeloma (MM) and healthy controls, this study also aimed to demonstrate the effect of SOCS-1 gene distribution and the effect of methylation of SOCS-1 on progression-free survival (PFS) and overall survival (OS).
Methods
This study included 120 patients diagnosed with MM between January 2018 and 2020 and 80 healthy individuals. The distribution of the SOCS-1 genotypes was statistically compared between MM patients and healthy controls. Additionally, the statistically significant effects of these genotypes on survival were examined.
Results
The CA/CA genotype of SOCS-1 was significantly higher in healthy controls (P =0.001), while the Del/Del genotype was significantly higher in patients with MM (P =0.034). The percent methylated reference (PMR) value of the SOCS-1 gene was significantly higher in the healthy controls (median, 43.48; range, 2.76‒247.75; P =0.001). Patients with a PMR value of ≥43.48 were 3.125 times more likely to develop progression than those with a PMR value of ＜43.48.
Conclusion
The effects of SOCS-1 polymorphisms on the pathogenesis of MM and SOCS-1 methylation will further shed light on the pathophysiology of MM.

Keyword

Multiple myeloma; SOCS-1; Epigenetics; Methylation; Survival

Figure

• 

  Fig. 1 Progression-free survival (PFS) analysis between patients’ subgroups in terms of SOCS-1 gene methylation status.

Reference

1. Morgan GJ, Davies FE, Linet M. 2002; Myeloma aetiology and epidemiology. Biomed Pharmacother. 56:223–34. DOI: 10.1016/S0753-3322(02)00194-4. PMID: 12199621.

2. Palumbo A, Avet-Loiseau H, Oliva S, et al. 2015; Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 33:2863–9. DOI: 10.1200/JCO.2015.61.2267. PMID: 26240224. PMCID: PMC4846284.

3. Fonseca R, Bergsagel PL, Drach J, et al. 2009; International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 23:2210–21. DOI: 10.1038/leu.2009.174. PMID: 19798094. PMCID: PMC2964268.

4. Depil S, Leleu X, Micol JB, et al. 2004; Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myeloma. Leuk Lymphoma. 45:2481–4. DOI: 10.1080/10428190412331283224. PMID: 15621764.

5. Guedes RA, Planello AC, Andia DC, De Oliveira NF, de Souza AP. 2015; Association of SOCS1 (-820) (rs33977706) gene polymorphism with chronic periodontitis: a case-control study in Brazilians. Meta Gene. 5:124–8. DOI: 10.1016/j.mgene.2015.06.005. PMID: 26199896. PMCID: PMC4506993.

6. Harada M, Nakashima K, Hirota T, et al. 2007; Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. Am J Respir Cell Mol Biol. 36:491–6. DOI: 10.1165/rcmb.2006-0090OC. PMID: 17099141.

7. Sharma A, Heuck CJ, Fazzari MJ, et al. 2010; DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med. 2:654–69. DOI: 10.1002/wsbm.89. PMID: 20890963.

8. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. 2003; SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 101:2784–8. DOI: 10.1182/blood-2002-06-1735. PMID: 12456503.

9. Depil S, Saudemont A, Quesnel B. 2003; SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. Leukemia. 17:1678–9. DOI: 10.1038/sj.leu.2403012. PMID: 12886263.

10. Reddy J, Shivapurkar N, Takahashi T, et al. 2005; Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene. 24:732–6. DOI: 10.1038/sj.onc.1208032. PMID: 15580314.

11. Singal R, Ginder GD. 1999; DNA methylation. Blood. 93:4059–70. DOI: 10.1182/blood.V93.12.4059. PMID: 10361102. PMCID: PMC9794904.

12. Duncan BK, Miller JH. 1980; Mutagenic deamination of cytosine residues in DNA. Nature. 287:560–1. DOI: 10.1038/287560a0. PMID: 6999365.

13. Fazzari MJ, Greally JM. 2004; Epigenomics: beyond CpG islands. Nat Rev Genet. 5:446–55. DOI: 10.1038/nrg1349. PMID: 15153997.

14. Cross SH, Bird AP. 1995; CpG islands and genes. Curr Opin Genet Dev. 5:309–14. DOI: 10.1016/0959-437X(95)80044-1. PMID: 7549424.

15. Oz Gul O, Cander S, Gul CB, Budak F, Oral B, Ersoy C. 2017; Cytokine signal suppressor (SOCS) 1-1478 CA/del gene polymorphism in Turkish patients with polycystic ovary syndrome. J Obstet Gynaecol. 37:896–901. DOI: 10.1080/01443615.2017.1309011. PMID: 28569589.

16. Chan MW, Chu ES, To KF, Leung WK. 2004; Quantitative detection of methylated SOCS-1, a tumor suppressor gene, by a modified protocol of quantitative real time methylation-specific PCR using SYBR green and its use in early gastric cancer detection. Biotechnol Lett. 26:1289–93. DOI: 10.1023/B:BILE.0000044922.43572.2d. PMID: 15483389.

17. Li B, Chen X, Jiang Y, et al. 2017; CCL2 promoter hypomethylation is associated with gout risk in Chinese Han male population. Immunol Lett. 190:15–9. DOI: 10.1016/j.imlet.2017.06.011. PMID: 28690186.

18. Ma H, Chen X, Hu H, et al. 2018; Hypermethylation of MDFI promoter with NSCLC is specific for females, non-smokers and people younger than 65. Oncol Lett. 15:9017–24. DOI: 10.3892/ol.2018.8535. PMID: 29805634. PMCID: PMC5958687.

19. Brand S, Zitzmann K, Dambacher J, et al. 2005; SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem Biophys Res Commun. 331:543–8. DOI: 10.1016/j.bbrc.2005.04.004. PMID: 15850793.

20. Yang T, Liu X, Kumar SK, Jin F, Dai Y. 2022; Decoding DNA methylation in epigenetics of multiple myeloma. Blood Rev. 51:100872. DOI: 10.1016/j.blre.2021.100872. PMID: 34384602.

21. Robak P, Drozdz I, Szemraj J, Robak T. 2018; Drug resistance in multiple myeloma. Cancer Treat Rev. 70:199–208. DOI: 10.1016/j.ctrv.2018.09.001. PMID: 30245231.

22. Pehlivan S, Serin I, Nursal AF, Oyaci Y, Gundes I, Pehlivan M. 202; What are the roles of global DNA and APC 2 gene promotor hypermethylation in multiple myeloma? Mol Biol Rep. 48:7875–82. DOI: 10.1007/s11033-021-06813-z. PMID: 34637096. PMCID: PMC8505470.

23. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. 2004; SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood. 103:4630–5. DOI: 10.1182/blood-2003-06-2007. PMID: 14976049.

24. Kalff A, Khong T, Mithraprabhu S, et al. 2019; Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). Leuk Lymphoma. 60:2143–51. DOI: 10.1080/10428194.2019.1571201. PMID: 31184224.

25. Reu FJ, Grabowski D, Mahfouz RZ, et al. 2015; A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 33(15 Suppl):8584. DOI: 10.1200/jco.2015.33.15_suppl.8584.

26. Khong T, Sharkey J, Spencer A. 2008; The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica. 93:860–9. DOI: 10.3324/haematol.12261. PMID: 18443271.